Clinical Trial Update: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial is evaluating adding venetoclax to standard chemotherapy for high-grade B-cell lymphomas, including diffuse large B-cell lymphoma and re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Diffuse Large B-cell Lymphoma Not Otherwise Specified
• Double Expressor Lymphoma
• Ebv-positive Diffuse Large B-cell Lymphoma Not Otherwise Specified
• High-grade B-cell Lymphoma
• High-grade B-cell Lymphoma with Myc and Bcl2 and or Bcl6 Rearrangements
• Transformed Indolent B-cell Non-hodgkin Lymphoma to Diffuse Large B-cell Lymphoma

Drugs mentioned

• Venetoclax (venetoclax)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING